New keratoconus treatment may prevent need for corneal transplant

Treatment TermsCorneal disease Additional SEO Keywords cornea, corneal disease, keratoconus, keratoconus treatment, collagen cross-linking, corneal collagen cross-linking, corneal cross-linking, SEO Meta Description Corneal collagen cross-linking, an FDA-approved treatment for the eye disease keratoconus, can preserve vision and prevent the need for a corneal transplant. Author MaryAnn Fletcher Sub-Title Cross-linking procedure can halt corneal changes, preserve vision Overview Corneal collagen cross-linking, an FDA-approved treatment for the eye disease keratoconus, can preserve vision and prevent the need for a corneal transplant. Content Blocks ContentUntil recently, people with keratoconus had few treatment options. The best their eye doctors could offer were increasingly stronger eyeglasses, special contact lenses, and eventually, in many cases, a corneal transplant. In spring 2016, the FDA approved a new treatment for this condition, which causes your corneas (the clear outer covering of the eye) to bulge gradually into a cone shape, distorting your vision. That treatment, called collagen cross-linking, or CXL, is now available at  Duke Eye Center, the first provider in North Carolina to offer it.“It’s is a long-awaited and very exciting development,” said Duke corneal specialistTerry Kim, MD. “Many patient and surgeons in the U.S. have been awaiting this procedure’s approval, as it has been used successfully in Europe for more than 10...
Source: dukehealth.org: Duke Health News - Category: Consumer Health News Authors: Source Type: news